ArticleeLife2022
EROS is a selective chaperone regulating the phagocyte NADPH oxidase and purinergic signalling.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Human inborn errors of the phagocyte respiratory burst: Chronic granulomatous disease and beyond.Journal of human immunity · 2026Article
- Molecular Views into the Synthesis and Activation of FlavocytochromeAntioxidants (Basel, Switzerland) · 2026Review
- Standardization of the use of opsonized zymosan as stimulus in the 1,2,3-dihydrorhodamine technique for the assessment of neutrophil respiratory burstBiomedica : revista del Instituto Nacional de Salud · 2024Article
- A nox2/cybb zebrafish mutant with defective myeloid cell reactive oxygen species production displays normal initial neutrophil recruitment to sterile tail injuries.G3 (Bethesda, Md.) · 2024Article
- Structural basis for EROS binding to human phagocyte NADPH oxidase NOX2.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Multidimensional Response Surface Methodology for the Development of a Gene Editing Protocol for p67Human gene therapy · 2024Article
- EROS is a selective chaperone regulating the phagocyte NADPH oxidase and purinergic signalling.eLife · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 10 institutions in 7 countries.
Lyra O Randzavola *Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom.ORCID 0000-0003-3463-1858
Paige M Mortimer *Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom.
Emma GarsideDepartment of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom.
Elizabeth R DufficyThe Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
Andrea SchejtmanMolecular Immunology Unit, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Georgia RoumeliotiFunctional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom.
Lu YuFunctional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom.
Mercedes PardoFunctional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom.
Kerstin SpirohnCenter for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, United States.
Charlotte TolleyWellcome Trust Sanger Institute, Hinxton, United Kingdom.
Cordelia BrandtWellcome Trust Sanger Institute, Hinxton, United Kingdom.
Katherine HarcourtWellcome Trust Sanger Institute, Hinxton, United Kingdom.
Esme NicholsDepartment of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom.
Mike NahorskiCambridge Institute of Medical Research, University of Cambridge, Cambridge, United Kingdom.
Geoff WoodsCambridge Institute of Medical Research, University of Cambridge, Cambridge, United Kingdom.
James C WilliamsonThe Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
Shreehari SureshThe Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
John M SowerbyThe Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
Misaki MatsumotoDepartment of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Celio X C SantosSchool of Cardiovascular Medicine and Sciences, James Black Centre, King's College London, London, United Kingdom.
Cher Shen KiarPeter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.
Subhankar MukhopadhyayPeter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.
William M RaeThe Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
Gordon J DouganThe Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
John GraingerFunctional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom.
Paul J LehnerThe Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.ORCID 0000-0001-9383-1054
Michael A CalderwoodCenter for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, United States.
Jyoti ChoudharyFunctional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom.
Simon ClareWellcome Trust Sanger Institute, Hinxton, United Kingdom.
Anneliese SpeakWellcome Trust Sanger Institute, Hinxton, United Kingdom.
Giorgia SantilliMolecular Immunology Unit, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Alex BatemanEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom.ORCID 0000-0002-6982-4660
Kenneth G C SmithThe Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
Francesca MagnaniDepartment of Biology and Biotechnology, University of Pavia, Pavia, Italy.ORCID 0000-0003-0812-9397
David C ThomasDepartment of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom.ORCID 0000-0002-9738-2329
University of Cambridge · GBImperial College London · GBInstitute of Cancer Research · CAWellcome Sanger Institute · GBKing's College London · GBHarvard University · USOrmond (United States) · USEuropean Bioinformatics Institute · GBKyoto Prefectural University of Medicine · JPUniversity of Pavia · IT
Funding
Biotechnology and Biological Sciences Research Council BB/L015129/1Medical Research Council MR/V011561/1Wellcome Trust 098051Wellcome Trust 206617/A/17/ZWellcome Trust 210688/Z/18/Z
Abstract
EROS (essential for reactive oxygen species) protein is indispensable for expression of gp91
Indexed as
Granulomatous Disease, ChronicNADPH OxidasesAnimalsHumansMicePhagocytesReactive Oxygen SpeciesSignal TransductionNADPH OxidasesReactive Oxygen Specieschaperone;immunologyinflammasomeinflammationmouseNADPH oxidase;OST complexP2X receptorT cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.